KYNB · Kyntra Bio, Inc.
AI read · Bad for KYNB
The AI's read
That puts Kyntra Bio at risk of losing its place on Nasdaq. The company failed the asset-and-sales test and other listing tests. A hearing pauses the suspension, so the stock can keep trading for now. Nasdaq could allow up to 180 more days, but it may refuse the request, and the company may not meet the rules.